Investor interest in the development of prescription digital therapeutics (PDTs) grew enormously in 2021, spurred by the telehealth boom of the pandemic. But determining approval pathways with regulators as well as methods to prove the value of prescription digital therapeutics (PDTs) will be essential in making sure that payers accept these very new treatments, according to Med Ad News’ annual special feature, “Value of Medicines.”
The pharmaceutical industry can expect continued pricing pressures in 2021, with only a slight nod of respect from the general public given to its activities in generating vaccines and therapies to fight the pandemic.
As the 2020 presidential election looms, debate about the price of prescription drugs and healthcare will intensify; healthcare communication leaders share their thoughts on how their pharma clients can be a constructive part of the conversations.
Value has so many meanings, but unfortunately the term has become synonymous with cost in the media/political landscape. As agency partners, we can help redefine how our clients communicate value to all audiences: HCPs, patients, caregivers, payers, investors, media at large and even to employees.
With Congressional hearings on drug prices, proposed rules for Medicare plans and new ICER efforts to link outcomes to value, finding answers on how to price and pay for drugs is still difficult.
With reports that the House Democratic leadership has agreed to hearings on Medicare for All, and a Harvard/Politico survey demonstrating that 84 percent of Democrats support a tax-funded national healthcare plan, the concept of Medicare for All is moving into the healthcare debate. At this point, however, Medicare for All is a concept defined by only general terms.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
